Literature DB >> 11687315

Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals.

K R Forward1, B M Willey, D E Low, A McGeer, M A Kapala, M M Kapala, L L Burrows.   

Abstract

Escherichia coli may become resistant to cephamycines and oxyimino cephalosporins by virtue of promotor and attenuator mutations or because they have acquired mobilized beta-lactamases from other gram-negative bacilli. This study examined Canadian strains to determine how often promotor and/or attenuator mutations account for this mechanism of resistance and the extent to which clonal spread of these organisms has occurred. We sequenced the promotor and attenuator region of 30 strains resistant to cefoxitin. Twenty-two strains had promotor mutations, 26 had attenuator mutations. Most promotor mutations resulted either in a change in the -35 promotor region towards the E. coli sigma 70 consensus sequence or in the creation of a new consensus hexamer upstream. Eight strains had mutations that increased the typical ampC 16-nucleotide spacer region to the consensus 17- or an 18-nucleotide sequence. Of the attenuator mutations, most did not substantially affect the attenuator loop. Several of the mutations have previously been described in South Africa, Scandinavia, and France. There was evidence that strains bearing certain mutations were clonally disseminated; however, the 11 strains bearing a complex set of attenuator mutations were not. The majority of cephamycin resistant E. coli strains in Toronto have attenuator and/or promotor mutations upstream of the chromosomal ampC gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687315     DOI: 10.1016/s0732-8893(01)00278-4

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  13 in total

1.  Practical approach for reliable detection of AmpC beta-lactamase-producing Enterobacteriaceae.

Authors:  Silke Polsfuss; Guido V Bloemberg; Jacqueline Giger; Vera Meyer; Erik C Böttger; Michael Hombach
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

2.  Evaluation of four phenotypic methods to detect plasmid-mediated AmpC β-lactamases in clinical isolates.

Authors:  M J Gude; C Seral; Y Sáenz; M González-Domínguez; C Torres; F J Castillo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-26       Impact factor: 3.267

3.  Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals.

Authors:  Michael R Mulvey; Elizabeth Bryce; David A Boyd; Marianna Ofner-Agostini; Allison M Land; Andrew E Simor; Shirley Paton
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 4.  A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.

Authors:  Pranita D Tamma; Yohei Doi; Robert A Bonomo; J Kristie Johnson; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

5.  Detection of AmpC beta-lactamase in Escherichia coli: comparison of three phenotypic confirmation assays and genetic analysis.

Authors:  S Peter-Getzlaff; S Polsfuss; M Poledica; M Hombach; J Giger; E C Böttger; R Zbinden; G V Bloemberg
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

6.  New method for laboratory detection of AmpC beta-lactamases in Escherichia coli and Klebsiella pneumoniae.

Authors:  K Nasim; S Elsayed; J D D Pitout; J Conly; D L Church; D B Gregson
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

7.  Characterization of cefoxitin-resistant Escherichia coli isolates from recreational beaches and private drinking water in Canada between 2004 and 2006.

Authors:  L F Mataseje; N Neumann; B Crago; P Baudry; G G Zhanel; M Louie; M R Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

Review 8.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

9.  Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary.

Authors:  Johann D D Pitout; Daniel B Gregson; Deirdre L Church; Kevin B Laupland
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

10.  Cephamycin resistance in clinical isolates and laboratory-derived strains of Escherichia coli, Nova Scotia, Canada.

Authors:  Brian Clarke; Margot Hiltz; Heather Musgrave; Kevin R Forward
Journal:  Emerg Infect Dis       Date:  2003-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.